June 21, 2022
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
June 2, 2022
OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma
April 25, 2022
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate OKI-179, an oral Class I HDAC inhibitor, for the treatment of both hematological and solid tumors, as well as exploring other validated oncology targets and pathways. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs.